Strategies for implementing long‐acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study

Strategies for implementing long‐acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study

Abstract Introduction Long‐acting cabotegravir (CAB LA) is the first LA agent approved for HIV pre‐exposure prophylaxis. EBONI (NCT05514509) is a Phase 4 implementation study evaluating the implementation of CAB LA delivery to Black cis‐ and transgender (cis‐and‐trans) women in clinics located in th...

Full description

Saved in:
Bibliographic Details
Main Authors: Katherine L. Nelson, Tammeka Evans Cooper, Yolanda Lawson, Dylan Baker, Satish Mocherla, Megan Dieterich, Theo Hodge, Alftan Dyson, Denise Sutherland‐Philips, Heidi Swygard, Lisa Petty, Peter Jeffery, Kenneth Sutton, Courtney Peasant Bonner, Sara M. Andrews, Samantha Chang, Piotr Budnik, Kimberly Smith, Annemiek deRuiter, Maggie Czarnogorski, Nanlesta Pilgrim
Format: Article
Language:English
Published: Wiley 2025-07-01
Series:Journal of the International AIDS Society
Subjects:
Black women
HIV prevention
implementation
long‐acting cabotegravir
pre‐exposure prophylaxis
sexual health
Online Access:https://doi.org/10.1002/jia2.26497
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/jia2.26497

Similar Items